Furmonertinib rechallenge for first-line third-generation EGFR TKI-resistant EGFR-mutant NSCLC: A retrospective propensity score-matched cohort study
Furmonertinib showed similar effectiveness and better safety compared with chemotherapy in NSCLC patients resistant to first-line third-generation EGFR TKIs. After matching, furmonertinib demonstrated numerically longer PFS than chemotherapy. Randomized controlled trials are warranted.
Authors
- Maolin Liu (ORCID: https://orcid.org/0000-0002-9505-6546)
- Dilimulati Abulizi
- Xi Chen (ORCID: https://orcid.org/0000-0001-8473-7920)
- Xue Hou (ORCID: https://orcid.org/0000-0002-5552-7569)
- Siqing Liu (ORCID: https://orcid.org/0000-0002-7235-1075)
- Jiaqi Zhao (ORCID: https://orcid.org/0000-0002-2950-6799)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.101003
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00